Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Portfolio News / By Libby Nunan Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting Read More »
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Portfolio News / By Libby Nunan A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster Read More »
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile Read More »
Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma Portfolio News / By Libby Nunan Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma Read More »
Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance Portfolio News / By Libby Nunan Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance Read More »
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting Read More »
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy Portfolio News / By Libby Nunan Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy Read More »
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics Portfolio News / By Libby Nunan Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics Read More »
Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million Portfolio News / By Libby Nunan Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million Read More »
Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting Portfolio News / By Libby Nunan Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting Read More »
